Investors Buy High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Key Points

• Unusually high call option activity: Investors bought 33,840 call options on Teva on Monday, a jump of about 73% above the average daily call volume of 19,561, signaling elevated bullish sentiment in the options market.
• Notable insider selling: Executive VPs Richard Daniell and Eliyahu Sharon Kalif sold 17,295 and 345,810 shares respectively, and insiders have sold a total of 948,499 shares worth $30.9M over the past three months while insiders now own just 0.55% of the company.
• Fundamentals and analyst optimism: Teva beat Q results (EPS $0.96 vs. $0.65 estimate; revenue $4.71B vs. $4.36B), set FY2026 EPS guidance of $2.57–$2.77, and has seen multiple price-target upgrades (Jefferies to $40, Barclays to $38) with a MarketBeat consensus of a "Moderate Buy" and average target of $37.67.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 33,840 call options on the company. This represents an increase of 73% compared to the average daily volume of 19,561 call options.

Insiders Place Their Bets

In other news, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the transaction, the executive vice president directly owned 85,755 shares of the company's stock, valued at $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the firm's stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the sale, the executive vice president owned 57,478 shares of the company's stock, valued at approximately $1,933,559.92. This represents a 85.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 948,499 shares of company stock worth $30,897,071 over the last three months. Company insiders own 0.55% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company's stock valued at $1,402,945,000 after acquiring an additional 7,255,083 shares in the last quarter. Phoenix Financial Ltd. lifted its holdings in Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock worth $834,164,000 after purchasing an additional 3,533,800 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its stake in Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company's stock worth $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock valued at $1,171,378,000 after acquiring an additional 5,917,423 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in Teva Pharmaceutical Industries by 14.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company's stock worth $1,167,323,000 after acquiring an additional 4,820,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA traded up $0.54 during midday trading on Monday, hitting $29.11. 2,528,348 shares of the company's stock were exchanged, compared to its average volume of 9,454,660. The firm has a market capitalization of $33.47 billion, a PE ratio of 24.30, a price-to-earnings-growth ratio of 9.56 and a beta of 0.72. The company's 50 day moving average price is $32.91 and its 200 day moving average price is $26.74. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analysts' expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company's quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, January 6th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 31st. Barclays lifted their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an "overweight" rating in a report on Friday, January 30th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an "overweight" rating in a report on Tuesday, December 16th. Finally, Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and an average price target of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.